Thursday, 06 October 2022



LATEST NEWS Will take steps for major electoral reforms : Kiren Rijiju IANS Review : 'Feels Like Home 2' is bigger, better and mature as it promises hearty entertainment 6 killed, 35 injured in Bangladesh bus-car collision Punjab Chief Minister Bhagwant Mann seeks intervention of MEA in murder of Punjabi family in US IND v SA, 1st ODI : Playing in the IPL helps with easy passing of information on Indian players : Kagiso Rabada Girl raped, murdered in UP's Mainpuri district Google updates Wear OS apps for upcoming Pixel Watch Delhi: 3 murders, 1 dowry killing reported in past 24 hrs IND v SA, 1st ODI : Rain forces delay in toss despite starting time pushed by 30 minutes Tri-series against Pakistan, Bangladesh will be great preparation for T20 World Cup : Kane Williamson S. Jaishankar hold talks with New Zealand counterpart, raises student visa issue Neetu Kapoor, Karisma Kapoor, Soni Razdan & others celebrate Alia Bhatt's baby shower ISRO getting ready its GSLV rocket for OneWeb satellite launch Gippy Grewal : 'Uchiyan Ne Gallan Tere Yaar Diyan' highlights women struggles Women's T20 Asia Cup : Thailand stun Pakistan for first win in event Jalpaiguri flash flood : West Bengal Chief Minister Mamata Banerjee announces financial aid to kin of dead, injured 10 killed in road accident in Pakistan 18 killed in firing in Mexico City Karnataka Chief Minister Basavaraj Bommai says will address Rahul Gandhi's concern on injured baby elephant immediately KVIC commemorates Gandhi Jayanti announces discounts on all products President of India graces Swachh Bharat Diwas celebrations


Can hormonal therapy raise brain tumour risk in women?

Health, Study, New Delhi, Research, Researchers, Hormonal Therapy, Brain Tumour

Web Admin

Web Admin

5 Dariya News

New Delhi , 07 Jun 2022

Hormonal therapy has emerged as one of the most advanced treatments for cancer, premature puberty, and excessive hair growth. But, doctors here on Tuesday warned people to be conscious about the therapy and undergo tumour screening as the high-doses of hormonal drugs can increase the risk of meningioma - the most common benign brain tumour - particularly in women.World Brain Tumour Day is observed annually on June 8 to raise awareness of the condition.

Meningioma is mostly a non-cancerous brain tumour arising in the layers of tissue (meninges) that surround and protect the brain and spinal cord. Although the majority of meningiomas are benign, these tumours can grow slowly until they are very large, if left undiscovered, and, in some locations, can be severely disabling and life-threatening.The fluctuations in meningioma growth during the menstrual cycle, pregnancy, and breastfeeding are well-documented.

These tumours have hormonal receptors in certain meningiomas located at the base of the skull."There is also an association between the growth of meningiomas and hormonal treatments, particularly prolonged and high dose use of the drug cyproterone acetate (CPA)," said Dr. Nagesh Chandra, Senior Consultant and HOD, Neurosurgery and Spine Surgery, Aakash Healthcare."The higher the dose, and the longer the drug is taken for, the greater the risk of meningioma," he added.

Cyproterone acetate is a steroid used in combination with ethinyl oestradiol to treat women with severe acne. But recent studies, published in peer-reviewed journals Scientific Reports and The BMJ showed high doses of the widely-used drug can raise the risk of brain tumour by seven-fold.In men it is used to treat inoperable prostate cancer, while in women it is used for conditions such as severe acne and excessive hair growth. Very small doses are also used in birth control pills and hormone replacement therapy.

The occurrence of meningiomas has been reported in association with the use of cyproterone acetate, primarily at doses of 25 mg/day and above."When hormone medicine doses are high and therapy is prolonged, the chances of meningioma formation increase. Meningioma develops in the tissues that surround and protect the brain and spinal cord (meninges). However, the risk decreases significantly after the treatment is discontinued," said Dr Arun Sharma, Consultant, Neurosurgeon, Indian Spinal Injuries Centre.

"We've had a number of cases of meningioma in our hospital in the last couple of years. All of them had long-term usage of high-dose cyproterone acetate. This drug's dosage ranges from 25mg to 100mg daily, depending on the patients' condition. It has been discovered that cyproterone acetate increases the risk of meningioma by a factor of around 10," Sharma added.However, it has been seen that the risk of meningioma decreases noticeably after the hormonal therapy is stopped. Therefore, it's essential that people who use high dose cyproterone acetate for at least three to five years should be informed about the increased risk of meningioma by their doctor.

Symptoms of meningioma include changes in vision, hearing loss or ringing in the ears, loss of smell, headaches, memory loss, seizures or weakness in arms and legs.If a patient is diagnosed with meningioma, treatment with cyproterone medicines must be stopped permanently, according to recommendations from the European Medicines Agency as well as the UK Health Security Agency. The agencies recommend women to take only daily doses of 10 mg. In men, cyproterone medicines should only be used to reduce sex drive in sexual deviations when other options for treatment are not suitable.

"Reasons for prescribing cyproterone acetate should also be clearly defined by the doctor. It should be prescribed with the lowest possible daily dose to avoid development of tumours in the body. When prolonged use of high dose cyproterone acetate is necessary, more thorough screening should be considered, and in patients with a documented meningioma, cyproterone acetate should be discontinued," Sharma noted.


Tags: Health , Study , New Delhi , Research , Researchers , Hormonal Therapy , Brain Tumour



related news




Photo Gallery



Video Gallery



5 Dariya News RNI Code: PUNMUL/2011/49000
© 2011-2022 | 5 Dariya News | All Rights Reserved
Powered by: CDS PVT LTD